HomeTrading IdeasAre Markets Underpricing the...

Are Markets Underpricing the Next Tariff Shock?

Economic activity appears set to strengthen in the official Q2 , but the second half of the year looks relatively vulnerable. One factor is the possibility that the simmering trade war may heat up after President Trump on Monday announced new tariffs set to begin on August 1. America’s biggest trade partners are targeted, including Japan and South Korea, which are set to face 25% tariffs, according to the President’s social media posts on Monday.

China on Tuesday warned President Trump against reigniting trade tensions, vowing to retaliate against any country that strikes deals with the U.S. aimed at cutting China out of global supply chains. While both nations reached a trade framework last month to ease tensions, the agreement remains vague on key details. Investors are now watching closely to see whether it can hold up under a potential new round of trade brinkmanship.

US Economy on Track to Rebound in Q2 – But Uncertainty Persists

The US economy remains on track to rebound in the second quarter after the modest contraction in Q1, but the expected bounce has downshifted, based on the median estimate for a set of nowcasts compiled by CapitalSpectator.com.

The upcoming Q2 GDP report is on track for a 1.7% increase in output, according to the median. Although that marks a downward revision from the median 2.3% rise for our , it still reflects a solid, if modestly diminished recovery following Q1’s 0.5% decline. The Bureau of Economic Analysis is scheduled to publish its initial Q2 data on July 30.

Tariff Uncertainty Puts Fed in a Tough Spot

For the moment, optimism relies on expectations that trade deals of one form or another will prevail, thereby blunting any negative effects. One area where uncertainty still persists, with implications for the economic outlook, is how the Federal Reserve navigates the evolving state of tariff policy. The central bank is concerned that an inflation effect from tariffs is only delayed rather than sidestepped and so a hawkish bias for policy is still warranted. Trump’s renewed focus on tariffs seems likely to keep the Fed in a wait-and-see mode for for deciding how and when to change its stance.

Fed funds futures are currently estimating a high probability (95%) for no change in the Fed funds target rate at the next policy meeting on July 30. By contrast, the market is pricing in a 64% probability for a rate cut in September. The question is whether those estimates will be affected by the tariff news in the days ahead, and if so, what will it mean for the economic outlook?

“The US does not actually want zero tariffs or a free-trade agreement with these countries,” said Hsien-Ming Lien, president of the Chung-Hua Institution for Economic Research, a think tank in Taipei, Taiwan. “What Trump really wants to do is to build up a manufacturing supply chain which has as little influence from China as possible.”

Most Popular

More from Author

Why CARGO Therapeutics Stock Is Gaining Today – Cargo Therapeutics (NASDAQ:CRGX)

CARGO Therapeutics Inc. CRGX saw its stock climb on Tuesday after...

Gold Prices Slip Amid Trump’s Tariff Delay and Fed Rate Cut Speculations

Gold Pressured by Trade Tariffs On Monday, U.S. President Donald Trump posted...

Artelo Biosciences Analyst See It As An Emerging Biotech – Artelo Biosciences (NASDAQ:ARTL)

D. Boral Capital upgraded Artelo Biosciences, Inc. ARTL on Tuesday.The analyst...

Read Now

Wall Street Is On Fire—So Why Is This Wall Of Cash Moving Abroad? – iShares Core MSCI Emerging Markets ETF (ARCA:IEMG)

U.S. stocks may be breaking records, but a flood of investor cash is moving elsewhere—toward emerging markets, where valuations are cheaper, currencies are strengthening and years of underperformance may finally be reversing.The iShares Core MSCI Emerging Markets ETF IEMG has attracted $7.4 billion in inflows so far...

Why CARGO Therapeutics Stock Is Gaining Today – Cargo Therapeutics (NASDAQ:CRGX)

CARGO Therapeutics Inc. CRGX saw its stock climb on Tuesday after the biotech firm announced a merger agreement with Concentra Biosciences LLC.Under the terms of the agreement, Concentra will acquire CARGO for $4.379 in cash per share, along with a non-transferable contingent value right.The CVR entitles shareholders...

Gold Prices Slip Amid Trump’s Tariff Delay and Fed Rate Cut Speculations

Gold Pressured by Trade Tariffs On Monday, U.S. President Donald Trump posted letters on Truth Social addressed to the leaders of 14 countries. He threatened to impose tariffs ranging from 25% to 40% on imports unless countries address trade imbalances. The letters targeted China, Germany, Japan, Mexico, and...

Artelo Biosciences Analyst See It As An Emerging Biotech – Artelo Biosciences (NASDAQ:ARTL)

D. Boral Capital upgraded Artelo Biosciences, Inc. ARTL on Tuesday.The analyst upgraded from Hold to Buy and introduced a price forecast of $20.Analyst Jason Kolbert wrote, “We continue to view Artelo as an emerging biotechnology company focused on Cachexia and chemotherapy-induced peripheral neuropathy (CIN) with the lead...

Oil Prices Rebound Despite OPEC+ Output Hike as Markets Rethink Supply Risk

surged yesterday after gapping down over the weekend. The gap down came about as the + group, which includes OPEC and its allies, agreed to increase oil production by 548,000 barrels per day in August. This is a bigger rise compared to the 411,000 barrels per day...

Asian Stocks Climb as Trump Signals Openness to Trade Talks Before Tariff Deadline

Asian stock markets remained steady despite the latest update on US President Donald Trump’s tariff plans. On Tuesday, the stayed strong, and dropped. In the US, stock prices fell after Trump sent letters to 14 countries, including Japan and South Korea, announcing much higher tariffs on...

Why Is Cogent Biosciences Stock Soaring On Tuesday? – Cogent Biosciences (NASDAQ:COGT)

On Monday, Cogent Biosciences, Inc. COGT said bezuclastinib showed meaningful clinical benefit for patients with non-advanced systemic mastocytosis.The company said that its experimental drug reduced the symptoms of a chronic immune disorder called non-advanced systemic mastocytosis.The latest study demonstrated meaningful and highly statistically significant improvements across the...

Does Higher Dose Of Wegovy Result In More Weight Loss – Novo Nordisk (NYSE:NVO)

Novo Nordisk A/S NVO on Tuesday announced that it has submitted an application to the European Medicines Agency (EMA) for approval of a new, higher dose of its obesity treatment, Wegovy (subcutaneous semaglutide 7.2 mg).The submission is based on clinical data from the STEP UP and STEP...

Why Is Penny Stock ProKidney Trading Higher On Tuesday? – ProKidney (NASDAQ:PROK)

ProKidney Corp. PROK stock is trading higher on Tuesday, with a session volume of 39.8 million compared to the average volume of 1.12 million as per data from Benzinga Pro.What happened: The chronic kidney disease (CKD)-focused company reported statistically significant and clinically meaningful positive topline results from...

US Dollar Regains Footing as Trump Shifts From Tariff Chaos to Control

Remember Trump’s Art of the ? It works. Two weeks ago, I noted that markets had reached "Peak Chaos" and that Trump’s tariff strategy would follow predictable patterns from his own documented playbook in The Art of the Deal. Today, as the July 9 deadline is due tomorrow...

Why Is Microcap Rallybio Stock Trading Higher On Tuesday? – Rallybio (NASDAQ:RLYB), Recursion Pharmaceuticals (NASDAQ:RXRX)

Rallybio Corporation RLYB agreed on Tuesday to sell its interest in REV102, an ENPP1 inhibitor in preclinical development for hypophosphatasia (HPP), to joint venture partner Recursion Pharmaceuticals Inc. RXRX.The deal consideration of up to $25 million includes an upfront equity payment of $7.5 million and near-term milestones.With...

Top 3 Markets for Prop Traders: EUR/USD, Gold, and Nasdaq Explained

Thinking about prop trading but not sure where to kick things off? You’ve come to the right place. Prop firms want traders who can deliver steady profits and survive the occasional drawdown and the first step is picking the right market. Out of the dozens of instruments...